Virax Biolabs
VRAX
5 hedge funds and large institutions have $57.1K invested in Virax Biolabs in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
150% more funds holding
Funds holding: 2 → 5 (+3)
99% more capital invested
Capital invested by funds: $28.6K → $57.1K (+$28.4K)
0.04% more ownership
Funds ownership: 0.04% → 0.09% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$45.8K |
| 2 |
VF
Virtu Financial
New York
|
+$16.3K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$3.81K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.55K |
| 5 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$24.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
1
HRT Financial
New York
| $36K | +$45.8K | +2,403 | New |
|
|
VF
2
Virtu Financial
New York
| $13K | +$16.3K | +855 | New |
|
|
3
National Bank of Canada
Montreal,
Quebec, Canada
| $6K | +$3.81K | +200 | +100% |
|
|
4
UBS Group
Zurich,
Switzerland
| $2.04K | +$2.55K | +134 | New |
|
|
FFA
5
Farther Finance Advisors
San Francisco,
California
| $13 | +$19 | +1 | New |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$24.7K | -1,206 | Closed |
|
VRAX Hedge Fund Activity: Q3 2025 in Review
5 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2025, worth a combined $57.1K — up 99% from $28.6K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VRAX positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $45.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $24.7K sold.
- 5 institutional investors held Virax Biolabs (VRAX) as of Q3 2025, up from 2 in Q2 2025.
- Funds reported $57.1K of Virax Biolabs stock for Q3 2025, up 99% quarter-over-quarter.
- 4 funds opened new Virax Biolabs positions in Q3 2025 and 1 closed out, a net change of +3 holders.
- The largest Virax Biolabs buyer in Q3 2025 was HRT Financial, an estimated $45.8K added.
- The largest Virax Biolabs seller in Q3 2025 was Citadel Advisors, an estimated $24.7K sold.
Based on aggregated 13F filings for Q3 2025.